This post was originally published on this site
https://i-invdn-com.investing.com/trkd-images/LYNXMPEHBM07G_L.jpg
The study, yet to be published in a peer-reviewed medical journal, showed antibody levels against Omicron after the booster shot were higher than antibodies in people who had been infected with and recovered naturally from COVID-19.
After a three-dose course of the vaccine, neutralising levels against Omicron were similar to those against the virus’s Delta variant after two doses, the company added.
The Anglo-Swedish drugmaker said researchers at Oxford University who carried out the study were independent from those who worked on the vaccine, Vaxzevria, with AstraZeneca.
